Blood test triggers preemptive strike on hidden colon cancer
NCT ID NCT03803553
Summary
This study is for people with stage III colon cancer who have finished their initial chemotherapy. It uses a special blood test to look for tiny, hidden traces of cancer. If the test is positive, patients are randomly assigned to either receive extra drug treatment or just be closely monitored, to see which approach better prevents the cancer from returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
Contact
-
Weill Cornell Medical College
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.